Non-ablative Immunotherapy to Prepare Bone Marrow for Transplant

May 2020 Council

Lead Division/Office


Point(s) of Contact

Terry Rogers Bishop, Ph.D.; Victoria Spruance, Ph.D.

Executive Summary

With the advent of Chimeric Antigen Receptor T-cells use for targeting cancer (“non-self”) tissue, the idea of targeting specific hematopoietic cells was a logical extension. CAR-T therapies for nonmalignant hematologic diseases is on the forefront of discovery. This workshop will explore the possibility of using non-myeloablative conditioning strategies and immunotherapies to improve the prognoses for autologous bone marrow transplantation when used to treat nonmalignant hematologic diseases.